Background:
Diabetes in pregnancy disproportionately affects minority and indigenous peoples. Continuous Glucose Monitoring (CGM) is a new technology that has potential to improve pregnancy outcomes. However inequities in access and use of CGM exist outside of pregnancy, and It is unclear to what extent minority and indigenous populations have been included in antenatal CGM research.
Objectives:
To describe the extent to which indigenous and/or not-white minority populations have been included
1. in research of CGM as part of antenatal care for improving obstetric and neonatal outcomes, or acceptability of CGM use in pregnancy.
2. To describe any specific methods implemented to reduce barriers to indigenous and minority peoples participation in randomised clinical trials (RCT).
Methods:
Scoping review conducted in accordance to JBI methodology. A systematic search was undertaken, across 2 databases and abstracts and full-texts were reviewed by two independent reviewers. Data was extracted to summary tables.
Results:
From 1209 references, 28 studies were identified assessing use of antenatal CGM on clinical outcomes and 11 assessing acceptability/satisfaction. Ethnicity was reported in 15/28 clinical outcomes studies and 3/11 studies assessing acceptability. In studies that reported ethnicity, participants were predominantly White-European / Caucasian. No RCTs described methodology to increase participation / retention of minority groups.
Discussion:
Ethnicity of participants in antenatal CGM research is not consistently reported. There are limited data on the impact of CGM in pregnancy amongst non-white and indigenous minority groups. A lack of adequate representation of these groups in research reduces generalisability of the findings and perpetuates inequities.